Summary: In a small randomised study in diabetic clinically significant macular edema, low-dose atorvastatin added to anti-VEGF injections gave more consistent visual and anatomical improvement than high-dose atorvastatin, though injection counts and serum VEGF changes did not differ significantly.
PICO Summary
| Element | Detail |
|---|---|
| Population | Type 2 diabetic patients with non-proliferative retinopathy and clinically significant macular edema. |
| Intervention | Low-dose atorvastatin (10–20 mg) plus three loading doses of intravitreal ranibizumab then PRN over 6 months (Group A). |
| Comparison | High-dose atorvastatin (30–40 mg) plus the same ranibizumab regimen (Group B). |
| Outcome | Mean injections 3.55 (A) vs 3.33 (B), not significant (p=0.24). Group A improved BCVA at 3 and 6 months with notable CMT reduction; Group B improved BCVA only at 3 months with less consistent CMT reduction. Serum VEGF fell in A and rose in B, but not significantly. |
Expert Commentary
This is an intriguing, counterintuitive signal that I would treat as hypothesis-generating rather than practice-shaping. The notion that low-dose atorvastatin might serve the retina better than high-dose, the opposite of the usual statin dose-response, is biologically conceivable given the retina’s particular cholesterol requirements, and the more durable visual and anatomical response in the low-dose arm is interesting. But the honest reading is cautious: the headline endpoints that would underpin a real claim, the number of anti-VEGF injections and the change in serum VEGF, did not differ significantly between groups, so the difference rests on softer functional and imaging comparisons in a small study with a brief six-month horizon. The mechanism is frankly speculative. Can I use this with my patients? Not as a reason to alter statin dosing. Statin intensity in a diabetic patient should be driven by cardiovascular risk, and I would not down-titrate a high-intensity statin for retinal reasons on this evidence. What it earns is a watching brief and coordination with ophthalmology. I would want a larger trial with injection burden as a primary endpoint before anything changes.
References
Markan A, Agarwal A, Katoch D, Bhadada S, Gupta V, Bansal R. Assessing the role of statins as an adjunctive anti-VEGF therapy for clinically significant macular edema (CSME) in type 2 diabetes mellitus. Rom J Ophthalmol. 2025;69(2):219–227. doi:10.22336/rjo.2025.35